Zhitong Finance App News, Watson Pharmaceuticals (002907.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”). After review, the CX001 extended-release tablet clinical trial application accepted on April 16, 2025 met the relevant requirements for drug registration, and it was agreed that this product would carry out clinical trials “for the treatment of post-herpes zoster neuralgia”.

Zhitongcaijing · 07/02 08:49
Zhitong Finance App News, Watson Pharmaceuticals (002907.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”). After review, the CX001 extended-release tablet clinical trial application accepted on April 16, 2025 met the relevant requirements for drug registration, and it was agreed that this product would carry out clinical trials “for the treatment of post-herpes zoster neuralgia”.